Sanara Medtech, Inc. (SMTI)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$34.73+0.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · SMTI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -9.5% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 14.7% |
Growth built into the price is above our model estimate.
The price assumes 24.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 26 industry peers · Company calendar date is not available
SMTI — divestiture
Dated 2026-07-29
of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely by Regulation FD. Forward-Looking Statements This communication relates to a proposed business combination transaction between MiMedx Group, Inc. (“MiMedx”) and Sanara MedTech Inc. (“Sanara”). This communication contains certain forward-looking statements within the meaning of the Private Securities Litigation Re…
Why it matters: A successful product launch could boost revenue. It may also improve market position.
Supportive ifOsStic BioAdhesive launched successfully in Q1 2027. This was done as planned.
Worry ifThe launch of OsStic BioAdhesive is delayed beyond Q1 2027.
Why it matters: The new product launch could bring in more money and boost the company's market position.
Supportive ifOsStic is successfully launched in Q1 2027 as planned.
Worry ifThe launch of OsStic is delayed beyond Q1 2027.
Why it matters: Meeting or beating guidance shows strong demand for Sanara's products and supports growth.
Supportive ifQ2 2026 net revenue reported between $28.5 million and $29.5 million.
Worry ifQ2 2026 net revenue reported below $28.5 million.
Why it matters: More surgeons and hospital contracts show strong market reach and product use.
Supportive ifSurgeon users grow a lot compared to last quarter, with products in over 4,000 hospitals.
Worry ifSurgeon users decline or fail to grow, with fewer than 4,000 hospitals contracted.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$152 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $491 loss on $10,000 · 4.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,429 loss on $10,000 · 54.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: New M&A activity may show growth chances. No activity could mean no progress.
Watch forAnnouncement of a new M&A agreement or partnership.
Also watch forNo new M&A announcements or agreements within the next quarter.
Why it matters: The merger could create a stronger company in surgical markets. It may boost revenue and market presence.
Supportive ifThe merger closes successfully by the end of the year with all approvals received.
Worry ifThe merger does not close. This is due to regulatory problems or shareholder rejection.
Why it matters: This would indicate a slowdown in growth, contrasting with previous quarters' performance.
Worry ifQ3 net revenue growth is reported below 10% year-over-year.
Less concerning ifQ3 net revenue growth exceeds 10% year-over-year.
Why it matters: Better income shows that the company is managing costs and making more money.
Supportive ifOperating income for Q3 shows an increase compared to Q2.
Worry ifOperating income for Q3 goes down compared to Q2.
Why it matters: A drop would signal potential issues with product mix or cost management.
Worry ifGross profit margin reported below 92% in Q3.
Less concerning ifGross profit margin remains at or above 92% in Q3.